Table 1 Treatment Duration and Time to Peak FEV1 Measure
|  | Mean, days ± SD | Median, days | Range, days (min - max) | Interquartile Range, days |
|---|---|---|---|---|
Antibiotic Treatment Duration | Â | Â | Â | Â |
All patients (n = 95) | 12.6 ± 3.2 | 13 | 23 (4 - 27) | 3 |
ceftaz/tobra treated (n = 50) | 12.5 ± 2.8 | 12.5 | 12 (4 - 16) | 3.75 |
mero/tobra treated (n = 45) | 12.8 ± 3.6 | 13 | 21 (6 - 27) | 3 |
FEV1 ≥ 70% predicted (n = 11) | 11.9 ± 2.4 | 12 | 8 (7 - 15) | 3 |
FEV1 40% - 69% predicted (n = 46) | 12.3 ± 2.8 | 13 | 15 (6 - 21) | 3 |
FEV1 < 40% predicted (n = 38) | 13.2 ± 3.8 | 14 | 23 (4 - 27) | 3 |
Time to Peak FEV 1 Measure | Â | Â | Â | Â |
All patients | 8.7 ± 4.0 | 10 | 19 (0 - 19) | 6.5 |
ceftaz/tobra treated | 8.9 ± 4.0 | 10 | 15 (1 - 16) | 6.75 |
mero/tobra treated | 8.5 ± 4.3 | 9 | 19 (0 - 19) | 5 |
FEV1 ≥ 70% predicted | 7.9 ± 3.3 | 7 | 12 (4 - 15) | 5 |
FEV1 40% - 69% predicted | 8.0 ± 4.2 | 9.5 | 15 (0 - 15) | 6 |
FEV1 < 40% predicted | 9.9 ± 3.6 | 10 | 16 (3 - 19) | 4.75 |